T. Rowe Price Associates’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | – | Sell |
-34,444
| Closed | -$77K | – | 3034 |
|
|
2021
Q4 | $77K | Sell |
34,444
-1,800
| -5% | -$4.52K | ﹤0.01% | 2901 |
|
|
2021
Q3 | $124K | Sell |
36,244
-10,700
| -23% | -$33K | ﹤0.01% | 2808 |
|
|
2021
Q2 | $140K | Buy |
46,944
+7,744
| +20% | +$24.5K | ﹤0.01% | 2791 |
|
|
2021
Q1 | $127K | Hold |
39,200
| – | – | ﹤0.01% | 2763 |
|
|
2020
Q4 | $83K | Hold |
39,200
| – | – | ﹤0.01% | 2636 |
|
|
2020
Q3 | $46K | Hold |
39,200
| – | – | ﹤0.01% | 2548 |
|
|
2020
Q2 | $35K | Sell |
39,200
-81,006
| -67% | -$77.2K | ﹤0.01% | 2472 |
|
|
2020
Q1 | $101K | Hold |
120,206
| – | – | ﹤0.01% | 2413 |
|
|
2019
Q4 | $115K | Hold |
120,206
| – | – | ﹤0.01% | 2449 |
|
|
2019
Q3 | $124K | Hold |
120,206
| – | – | ﹤0.01% | 2435 |
|
|
2019
Q2 | $216K | Hold |
120,206
| – | – | ﹤0.01% | 2395 |
|
|
2019
Q1 | $226K | Hold |
120,206
| – | – | ﹤0.01% | 2379 |
|
|
2018
Q4 | $142K | Hold |
120,206
| – | – | ﹤0.01% | 2458 |
|
|
2018
Q3 | $326K | Hold |
120,206
| – | – | ﹤0.01% | 2330 |
|
|
2018
Q2 | $230K | Buy |
120,206
+43,300
| +56% | +$87.5K | ﹤0.01% | 2421 |
|
|
2018
Q1 | $162K | Sell |
76,906
-145,154
| -65% | -$311K | ﹤0.01% | 2445 |
|
|
2017
Q4 | $451K | Sell |
222,060
-45,400
| -17% | -$94.2K | ﹤0.01% | 2128 |
|
|
2017
Q3 | $356K | Hold |
267,460
| – | – | ﹤0.01% | 2214 |
|
|
2017
Q2 | $420K | Sell |
267,460
-135
| -0.1% | -$260 | ﹤0.01% | 2126 |
|
|
2017
Q1 | $864K | Sell |
267,595
-16,000
| -6% | -$39.4K | ﹤0.01% | 1843 |
|
|
2016
Q4 | $383K | Sell |
283,595
-365
| -0.1% | -$477 | ﹤0.01% | 2161 |
|
|
2016
Q3 | $443K | Buy |
283,960
+173,360
| +157% | +$266K | ﹤0.01% | 2063 |
|
|
2016
Q2 | $147K | Sell |
110,600
-282,260
| -72% | -$1.32M | ﹤0.01% | 2378 |
|
|
2016
Q1 | $2.07M | Sell |
392,860
-220,860
| -36% | -$1.35M | ﹤0.01% | 1512 |
|
|
2015
Q4 | $4.82M | Sell |
613,720
-29,400
| -5% | -$253K | ﹤0.01% | 1424 |
|
|
2015
Q3 | $5.43M | Buy |
643,120
+11,800
| +2% | +$109K | ﹤0.01% | 1424 |
|
|
2015
Q2 | $6.91M | Buy |
631,320
+8,600
| +1% | +$110K | ﹤0.01% | 1428 |
|
|
2015
Q1 | $8.71M | Sell |
622,720
-269,350
| -30% | -$4.12M | ﹤0.01% | 1371 |
|
|
2014
Q4 | $15.1M | Sell |
892,070
-133,150
| -13% | -$1.94M | ﹤0.01% | 1209 |
|
|
2014
Q3 | $13.8M | Buy |
1,025,220
+402,700
| +65% | +$4.8M | ﹤0.01% | 1220 |
|
|
2014
Q2 | $7.93M | Buy |
622,520
+6,300
| +1% | +$65.6K | ﹤0.01% | 1362 |
|
|
2014
Q1 | $7.33M | Buy |
616,220
+5,700
| +0.9% | +$76.5K | ﹤0.01% | 1366 |
|
|
2013
Q4 | $8.43M | Sell |
610,520
-2,561,896
| -81% | -$36.2M | ﹤0.01% | 1335 |
|
|
2013
Q3 | $55.4M | Sell |
3,172,416
-84,400
| -3% | -$1.62M | 0.01% | 781 |
|
|
2013
Q2 | $52.9M | Buy |
+3,256,816
| New | +$101M | 0.01% | 769 |
|
Other funds holding INFI
BI
GC
T. Rowe Price Associates's INFI Position: Q1 2022 in Review
T. Rowe Price Associates sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q1 2022, closing a stake of 34,444 shares — an estimated $77K sold.
T. Rowe Price Associates first reported a position in INFI in Q2 2013 and held it in 35 quarters. The position peaked at $55.4M in Q3 2013. 93 funds tracked by Wall St. Rank hold INFI as of Q1 2022.
- T. Rowe Price Associates reported no remaining Infinity Pharmaceuticals, Inc. position as of Q1 2022 after selling out during the quarter.
- T. Rowe Price Associates sold 34,444 Infinity Pharmaceuticals, Inc. shares in Q1 2022, an estimated $77K.
- T. Rowe Price Associates first reported a position in Infinity Pharmaceuticals, Inc. in Q2 2013 and held it in 35 quarters.
- T. Rowe Price Associates's Infinity Pharmaceuticals, Inc. position peaked at $55.4M in Q3 2013.
- 93 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q1 2022.
Based on T. Rowe Price Associates's 13F filing for Q1 2022, filed 16 May 2022.